mycophenolic acid accord 180 mg gastro - resistant tablets
accord healthcare limited - Микофеноловая киселина - 180 mg gastro - resistant tablets
zoledronic acid acepharma 4 mg/5 ml concentrate for solution for infusion
Ейсфарма ООД - Золедроновая киселина - 4 mg/5 ml concentrate for solution for infusion
alendronic acid aurobindo 70 mg tablets
aurobindo pharma (malta) limited - alendronic киселина - 70 mg tablets
zoledronic acid sandoz 4 mg/5 ml concentrate for solution for infusion
sandoz d.d. - Золедроновая киселина - 4 mg/5 ml concentrate for solution for infusion
zoledronic acid sandoz 4 mg/100 ml solution for infusion
sandoz d.d. - Золедроновая киселина - 4 mg/100 ml solution for infusion
ibandronic acid sandoz 3 mg/3 ml solution for injection
sandoz d.d. - Ибандронатом - 3 mg/3 ml solution for injection
ibandronic acid teva 6 mg/6 ml concentrate for solution for infusion
Тева Фармасютикълс България ЕООД - Ибандронатом - 6 mg/6 ml concentrate for solution for infusion
ibandronic acid teva 3 mg/3 ml solution for injection in pre - filled sypringe
Тева Фармасютикълс България ЕООД - Ибандронатом - 3 mg/3 ml solution for injection in pre - filled sypringe
ibandronic acid stada 150 mg film - coated tablets
stada arzneimittel ag - Ибандронатом - 150 mg film - coated tablets
tyenne
fresenius kabi deutschland gmbh - тоцилизумаб - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - Имуносупресори - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.